Premium
Targeted siRNA delivery using aptamer‐siRNA chimeras and aptamer‐conjugated nanoparticles
Author(s) -
Sivakumar Padmanaban,
Kim Sumin,
Kang Han Chang,
Shim Min Suk
Publication year - 2018
Publication title -
wiley interdisciplinary reviews: nanomedicine and nanobiotechnology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.175
H-Index - 72
eISSN - 1939-0041
pISSN - 1939-5116
DOI - 10.1002/wnan.1543
Subject(s) - aptamer , nanocarriers , small interfering rna , rna interference , nanomedicine , gene silencing , nucleic acid , rna , targeted drug delivery , drug delivery , computational biology , biology , chemistry , microbiology and biotechnology , nanotechnology , gene , biochemistry , nanoparticle , materials science , organic chemistry
The sequence‐specific gene‐silencing ability of small interfering RNA (siRNA) has been exploited as a new therapeutic approach for the treatment of a variety of diseases. However, efficient and safe delivery of siRNA into target cells is still a challenge in the clinical development of siRNA‐based therapeutics. Recently, nucleic acid‐based aptamers that target cell surface proteins have emerged as a new class of targeting moieties due to their high specificity and avidity. To date, various aptamer‐mediated siRNA delivery systems have been developed to enhance the RNA interference (RNAi) efficacy of siRNA via targeted delivery. In this review, we summarize recent advances in developing aptamer‐mediated siRNA delivery systems for RNAi therapeutics, mainly aptamer–siRNA chimeras and aptamer‐functionalized nanocarriers incorporating siRNA, with a focus on their molecular designs and formulations. In addition, the challenges and engineering strategies of aptamer‐mediated siRNA delivery systems for clinical translation are discussed. This article is categorized under: Biology‐Inspired Nanomaterials > Nucleic Acid‐Based Structures Therapeutic Approaches and Drug Discovery > Nanomedicine for Oncologic Disease